OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kang on Key Results From the PALOMA-2 and PALOMA-3 Trials in Advanced Breast Cancer

October 31st 2022

Irene Morae Kang, MD, discusses key overall survival data from the phase 3 PALOMA-2 and PALOMA-3 trials, which evaluated the addition of palbociclib to standard endocrine therapy for patients with advanced breast cancer.

Dr. Dzienis on Use of Pembrolizumab with Carboplatin and Paclitaxel in HNSCC

October 31st 2022

Marcin Dzienis, MD, discusses the use of pembrolizumab with carboplatin and paclitaxel in head and neck squamous cell carcinoma .

Dr. Hamid on the Evolving Treatment of Immunotherapy in Patients With Solid Tumors

October 31st 2022

Omid Hamid, MD, discusses the evolving treatment of immunotherapy in patients with solid tumors.

Dr. Sonpavde on the Investigation of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

October 31st 2022

Guru P. Sonpavde, MD, discusses the investigation of enfortumab vedotin-ejfv with or without pembrolizumab in urothelial cancer.

Women in Oncology: Leaving Passionate Legacies

October 28th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the scientific achievements they have witnessed in the field of leukemia and their hopes for the future of treating this disease.

Women in Oncology: The Value of Female Leadership

October 28th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss how they turned career obstacles into opportunities and what they have learned from being women in the leukemia field.

Dr. Bourhis on the OS Benefit of Xevinapant Plus Chemoradiotherapy in HNSCC

October 28th 2022

Jean Bourhis, MD, PhD, discusses the overall survival benefit of xevinapant plus chemoradiotherapy in head and neck squamous cell carcinoma.

Dr. Politi on Drug-Tolerant Persister Cells in Cancer Care

October 28th 2022

Katerina Politi, PhD, discusses drug-tolerant persister cells in patients with cancer.

Dr. Gibbs on the Role of ctDNA in Predicting Distant vs Locoregional Recurrence in CRC

October 27th 2022

Peter Gibbs, MBBS, MD, FRACP, discusses the role of circulating tumor DNA in predicting distant vs locoregional recurrence in colorectal cancer.

Dr. Moore on the Investigation of Nab-sirolimus in TSC1/2-Mutated Gynecologic Cancers and Other Solid Tumors

October 27th 2022

Kathleen N. Moore, MD, MS, discusses the investigation of nab-sirolimus in TSC1/2-mutated gynecologic cancers.

Dr. Rampal on ACVR1 Inhibition With Pacritinib in Myelofibrosis

October 27th 2022

Raajit K. Rampal, MD, PhD, discusses the investigation of ACVR1 inhibition as a mechanism for improving anemia in patients with myelofibrosis.

Women in Oncology: Opportunities for Success Through Mentorship

October 27th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the importance of strong mentorship relationships and the unique growth opportunities they found at different points of their careers.

Women in Oncology: Actively Preparing for Advances in Leukemia Treatment

October 27th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the toughest challenges they faced in the leukemia field at the start of their fellowships and careers.

Dr. Maziéres on the Evaluation of Tepotinib Plus Osimertinib in EGFR-mutated NSCLC

October 26th 2022

Julien Maziéres, MD, PhD, discusses the evaluation of tepotinib plus osimertinib in EGFR-mutated non–small cell lung cancer.

Dr. Ueno on Patient-Reported Outcomes With Trastuzumab Deruxtecan in HR+/HER2-Low Breast Cancer

October 26th 2022

Naoto T. Ueno, MD, PhD, FACP, discusses patient-reported outcomes with fam-trastuzumab deruxtecan-nxki (Enhertu) in hormone receptor (HR)–positive/HER2-low metastatic breast cancer.

Dr. Cohen on the Use of ctDNA for Chemotherapy Decisions in CRC

October 26th 2022

Stacey A. Cohen, MD, discusses the evaluation of the role of circulating tumor DNA to determine the benefit of chemotherapy in colorectal cancer.

Dr. Garfall of the FDA Approval of Teclistamab in Relapsed/Refractory Multiple Myeloma

October 25th 2022

Alfred L. Garfall, MD, discusses the significance of the FDA approval of teclistamab-cqyv in relapsed/refractory multiple myeloma and how this agent might fit into the treatment paradigm going forward.

Dr. Kalinsky on the Importance of Molecular Profiling in Breast Cancer

October 25th 2022

Kevin Kalinsky, MD, MS, discusses the importance of molecular profiling in breast cancer.

Dr. Borad on the Next Steps for Research Evaluating RLY-4008 in FGFR2+ Cholangiocarcinoma

October 25th 2022

Mitesh Borad, MD, discusses the next steps for investigating RLY-4008 in cholangiocarcinoma harboring FGFR2 fusion or rearrangement.

Dr. DiSilvestro on the Long-Term OS Benefit of Olaparib Maintenance in Ovarian Cancer

October 24th 2022

Paul A. DiSilvestro, MD, discusses the long-term survival benefit of olaparib maintenance in advanced BRCA-mutated ovarian cancer.